Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.
about
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's DiseaseThe pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptorUpregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.Effects of Adolescent Intermittent Alcohol Exposure on the Expression of Endocannabinoid Signaling-Related Proteins in the Spleen of Young Adult Rats.Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.Endocannabinoids in the gastrointestinal tract.Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.Nociceptor plasticity: A closer look.Chemical tools to modulate 2-arachidonoylglycerol biosynthesis.Polyunsaturated fatty acids and endocannabinoids in health and disease.Metabolic differentiation of early Lyme disease from southern tick-associated rash illness (STARI).Palmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing.The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.A flow cytometry assay to quantify intercellular exchange of membrane components.Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia.N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications.Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans.Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse.Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls.An involvement of phospholipase A/acyltransferase family proteins in peroxisome regulation and plasmalogen metabolism.Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the Translational Silencer, T-cell Intracellular Antigen-1.Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.Ultramicronized palmitoylethanolamide counteracts the effects of compound 48/80 in a canine skin organ culture model.Endocannabinoids in Caenorhabditis elegans are essential for the mobilization of cholesterol from internal reserves.Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy.Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect.The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors.Extrasynaptic Neurotransmission Mediated by Exocytosis and Diffusive Release of Transmitter Substances.Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy
P2860
Q26746050-E449DD93-380F-484B-9070-251AE7E8489DQ31122398-181CAEBF-0663-4ABB-B6C4-5DD3D03FE53EQ33671206-EE24811D-E04F-4BB2-B00B-F325684F24D4Q33746277-79C24D6F-9678-441E-9FC7-9E05CDC0BA1CQ36143007-93543D64-2AA7-4763-9ADA-55F480C4EA45Q38715276-C49D936E-C85A-4C08-B317-6488A8BEA6B8Q38931168-0B1557BE-B9F6-486D-AEDD-7E9C39934624Q38973739-85D9DA75-476F-4EE9-B390-B603443577DFQ39295296-E04BEC9A-E720-4F47-BFB9-C85ACF6959E7Q39356480-FD273614-C748-411E-A932-86BBB561251AQ39421016-326A1DD1-1495-4C7A-86B8-F5BFD2E4342FQ40091071-8AEFC307-B940-44A3-ABA6-C0AD163790D2Q41152448-A6ED4F16-9D3C-41D6-A1FB-D0CAC3EA6F2EQ41660878-03C392F6-76A1-4A8C-9450-43148B35E54CQ42143992-AA417F4E-16D5-4AE2-ACC7-D495191A2F01Q42220056-C78B089E-3146-49DB-862F-A380C6E90F54Q42714635-ABF32482-73AA-4BEA-A2DE-1F75B4348505Q46799280-266FC804-3C01-427F-A6C2-C0C3DC615820Q47141476-1717EFDE-6F9D-4427-B09A-510D2551F53FQ47222146-FDCCBEC6-B202-4519-B480-A28CFB3B63E3Q47363203-E4FF17C7-4C94-4B86-AEB7-CBE40C034A5DQ47819519-3778587C-D702-4666-9DE0-564DA83ED12EQ47862623-79FF8FE7-CD54-4D7E-8B1B-7EA033148E6BQ48242279-6BA70D77-5961-49D2-A1E4-C513243DCBA1Q48323713-9F32B158-9B73-4599-9312-BE803A8504F2Q52311781-00D731E8-4E59-4577-A985-8FF13A0E3A74Q52316988-86A4DEB2-594D-4AA3-AAF0-2C9B87452D83Q52608759-64548621-661F-4F14-B55C-EF633FD34B07Q55077096-D8E575F0-B0F1-42D3-9E61-D9D55DF020B4Q55250013-40352445-B539-4528-AD82-D9B323D82E00Q59128911-A2F3F48A-24DC-4B8C-B270-00D0FB34ED95
P2860
Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Endocannabinoids and endocanna ...... ole in neurological disorders.
@en
type
label
Endocannabinoids and endocanna ...... ole in neurological disorders.
@en
prefLabel
Endocannabinoids and endocanna ...... ole in neurological disorders.
@en
P1476
Endocannabinoids and endocanna ...... ole in neurological disorders.
@en
P2093
Stefania Petrosino
P304
P356
10.1016/J.PLIPRES.2016.02.002
P577
2016-03-07T00:00:00Z